Abstract：
OBJECTIVE: To provide an update on the current state of percutaneous thermal ablation in the treatment of sarcoma.
RESULTS: Data continue to accrue in support of ablation for local control and palliation of specific sarcoma subtypes such as extra-abdominal desmoid fibromatosis and for broader indications such as the treatment of oligometastatic disease. The synergistic possibilities of various combination therapies such as cryoablation and immunotherapy represent intriguing areas of active investigation. Histotripsy is an emerging non-invasive, non-thermal ablative modality that may further expand the therapeutic arsenal for sarcoma treatment. Percutaneous thermal ablation is a valuable tool in the multidisciplinary management of sarcoma, offering a minimally invasive adjunct to surgery and radiation therapy. Although there remains a paucity of high-level evidence specific to sarcomas, ablation techniques are demonstrably safe and effective for achieving local tumor control and providing pain relief in select patients and are of particular benefit in those with metastatic disease or requiring palliative care.
RESULTS: Data continue to accrue in support of ablation for local control and palliation of specific sarcoma subtypes such as extra-abdominal desmoid fibromatosis and for broader indications such as the treatment of oligometastatic disease. The synergistic possibilities of various combination therapies such as cryoablation and immunotherapy represent intriguing areas of active investigation. Histotripsy is an emerging non-invasive, non-thermal ablative modality that may further expand the therapeutic arsenal for sarcoma treatment. Percutaneous thermal ablation is a valuable tool in the multidisciplinary management of sarcoma, offering a minimally invasive adjunct to surgery and radiation therapy. Although there remains a paucity of high-level evidence specific to sarcomas, ablation techniques are demonstrably safe and effective for achieving local tumor control and providing pain relief in select patients and are of particular benefit in those with metastatic disease or requiring palliative care.
摘要：
目的：提供经皮热消融治疗肉瘤的最新状态。
结果：继续积累的数据支持消融以局部控制和缓解特定肉瘤亚型，例如腹外纤维瘤病，以及更广泛的适应症，例如治疗寡转移疾病。各种组合疗法如冷冻消融和免疫疗法的协同可能性代表了活跃研究的有趣领域。组织切片是一种新兴的非侵入性，非热消融方式，可以进一步扩大肉瘤治疗的治疗范围。经皮热消融是肉瘤多学科治疗的重要工具,为手术和放射治疗提供微创辅助。尽管仍然缺乏针对肉瘤的高级证据，在部分患者中,消融技术对于实现局部肿瘤控制和缓解疼痛是安全有效的,对于转移性疾病或需要姑息治疗的患者尤其有益.
结果：继续积累的数据支持消融以局部控制和缓解特定肉瘤亚型，例如腹外纤维瘤病，以及更广泛的适应症，例如治疗寡转移疾病。各种组合疗法如冷冻消融和免疫疗法的协同可能性代表了活跃研究的有趣领域。组织切片是一种新兴的非侵入性，非热消融方式，可以进一步扩大肉瘤治疗的治疗范围。经皮热消融是肉瘤多学科治疗的重要工具,为手术和放射治疗提供微创辅助。尽管仍然缺乏针对肉瘤的高级证据，在部分患者中,消融技术对于实现局部肿瘤控制和缓解疼痛是安全有效的,对于转移性疾病或需要姑息治疗的患者尤其有益.
